GleamWall
中文EN

KRRO Korro Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1703647 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-82.5%
TTM net income YoY-20.0%
TTM EPS YoY5.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-8,467.3%
Net margin-8,214.5%
FCF margin-4,943.8%
EBITDA margin-8,325.8%

Returns

ROE-113.3%
ROA-68.5%
ROIC (approx.)-140.5%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets40.3%
Debt / equity0.00x
Current ratio7.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.60x
Accruals ratio-27.4%
Payout ratio—
Capex / revenue13.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$6.39M$2.27M
R&D expense$65.58M$63.64M
SG&A expense$28.16M$30.55M
Operating income-$121.86M-$91.91M
Pretax income-$116.62M-$83.44M
Income tax$637,000$141,000
Net income-$117.26M-$83.58M
EBITDA-$117.58M-$88.34M
EPS (basic)-12.48-9.37
EPS (diluted)-12.48-9.37
Weighted avg. shares (diluted)9.40M8.92M
Balance sheet
Cash & equivalents$21.82M$55.64M
Short-term investments$53.33M$70.45M
Current assets$82.37M$131.53M
PP&E, net$8.16M$27.71M
Total assets$113.51M$226.24M
Current liabilities$11.94M$14.96M
Total liabilities$62.07M$65.83M
Shareholders' equity$51.44M$160.41M
Shares outstanding9.42M9.38M
Cash flow statement
Operating cash flow-$78.56M-$60.07M
Capital expenditure$518,000$17.90M
Free cash flow-$79.08M-$77.98M
Investing cash flow$43.99M-$123.35M
Financing cash flow$685,000$69.36M
Depreciation & amortization$4.28M$3.56M
Stock-based compensation$7.66M$4.46M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.